ViroMed to go global

Published: 2008-11-07 06:31:00

Updated: 2008-11-07 06:31:00

ViroMed Co. plans to enter into a technology transfer or licensing transaction with respect to VM202, one of the plasmid-based therapeutics for the prevention and treatment of cardiovascular disease.

In the recently held “Korea Bio Biz Day 2008” hosted by the Korea Trade-Investment Promotion ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK